# Iradimed Corp: financial statements, quarterly

IRMD · Nasdaq · CIK 1325618 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/irmd.md) · [Financials](/companies/irmd/financials.md) · [Filings](/companies/irmd/filings.md) · [Insiders](/companies/irmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/irmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [16.5](/filings/0001558370-24-014056.md) | [17.5 d](/filings/0001558370-25-011853.md) | [17.6](/filings/0001558370-25-006308.md) | [17.9](/filings/0001558370-25-009987.md) | [18.3](/filings/0001104659-25-105538.md) | [19.4 d](/filings/0001104659-26-024691.md) | [19.5](/filings/0001628280-26-029325.md) | [20.4](/filings/0001628280-26-051402.md) | [21.2](/filings/0001104659-25-105538.md) | [22.7 d](/filings/0001104659-26-024691.md) | [22.0](/filings/0001628280-26-029325.md) | [20.5](/filings/0001628280-26-051402.md) |
| Cost of revenue | $m | [3.7](/filings/0001558370-24-014056.md) | [4.0 d](/filings/0001558370-25-011853.md) | [4.2](/filings/0001558370-25-006308.md) | [3.9](/filings/0001558370-25-009987.md) | [4.1](/filings/0001104659-25-105538.md) | [4.6 d](/filings/0001104659-26-024691.md) | [4.7](/filings/0001628280-26-029325.md) | [4.5](/filings/0001628280-26-051402.md) | [4.7](/filings/0001104659-25-105538.md) | [5.7 d](/filings/0001104659-26-024691.md) | [5.2](/filings/0001628280-26-029325.md) | [5.3](/filings/0001628280-26-051402.md) |
| Gross profit | $m | [12.8](/filings/0001558370-24-014056.md) | [13.4 d](/filings/0001558370-25-011853.md) | [13.4](/filings/0001558370-25-006308.md) | [14.0](/filings/0001558370-25-009987.md) | [14.2](/filings/0001104659-25-105538.md) | [14.8 d](/filings/0001104659-26-024691.md) | [14.8](/filings/0001628280-26-029325.md) | [16.0](/filings/0001628280-26-051402.md) | [16.5](/filings/0001104659-25-105538.md) | [17.0 d](/filings/0001104659-26-024691.md) | [16.8](/filings/0001628280-26-029325.md) | [15.2](/filings/0001628280-26-051402.md) |
| Research and development | $m | [0.5](/filings/0001558370-24-014056.md) | [0.7 d](/filings/0001558370-25-011853.md) | [0.8](/filings/0001558370-25-006308.md) | [0.8](/filings/0001558370-25-009987.md) | [0.6](/filings/0001104659-25-105538.md) | [0.6 d](/filings/0001104659-26-024691.md) | [0.6](/filings/0001628280-26-029325.md) | [0.9](/filings/0001628280-26-051402.md) | [0.7](/filings/0001104659-25-105538.md) | [0.8 d](/filings/0001104659-26-024691.md) | [1.0](/filings/0001628280-26-029325.md) | [0.7](/filings/0001628280-26-051402.md) |
| Operating income | $m | [5.9](/filings/0001558370-24-014056.md) | [5.2 d](/filings/0001558370-25-011853.md) | [4.7](/filings/0001558370-25-006308.md) | [5.6](/filings/0001558370-25-009987.md) | [5.8](/filings/0001104659-25-105538.md) | [5.8 d](/filings/0001104659-26-024691.md) | [5.4](/filings/0001628280-26-029325.md) | [6.8](/filings/0001628280-26-051402.md) | [6.8](/filings/0001104659-25-105538.md) | [7.1 d](/filings/0001104659-26-024691.md) | [7.2](/filings/0001628280-26-029325.md) | [6.4](/filings/0001628280-26-051402.md) |
| Income tax | $m | [1.3](/filings/0001558370-24-014056.md) | [1.1 d](/filings/0001558370-25-011853.md) | [1.1](/filings/0001558370-25-006308.md) | [1.4](/filings/0001558370-25-009987.md) | [1.4](/filings/0001104659-25-105538.md) | [1.2 d](/filings/0001104659-26-024691.md) | [1.3](/filings/0001628280-26-029325.md) | [1.6](/filings/0001628280-26-051402.md) | [1.7](/filings/0001104659-25-105538.md) | [1.3 d](/filings/0001104659-26-024691.md) | [2.0](/filings/0001628280-26-029325.md) | [1.7](/filings/0001628280-26-051402.md) |
| Net income | $m | [5.1](/filings/0001558370-24-014056.md) | [4.5 d](/filings/0001558370-25-011853.md) | [4.1](/filings/0001104659-25-105538.md) | [4.9](/filings/0001104659-25-105538.md) | [5.0](/filings/0001104659-25-105538.md) | [5.1 d](/filings/0001104659-26-024691.md) | [4.7](/filings/0001628280-26-051402.md) | [5.8](/filings/0001628280-26-051402.md) | [5.6](/filings/0001104659-25-105538.md) | [6.4 d](/filings/0001104659-26-024691.md) | [5.8](/filings/0001628280-26-051402.md) | [5.2](/filings/0001628280-26-051402.md) |
| Diluted EPS | $ per share | [0.40](/filings/0001558370-24-014056.md) | not reported | [0.32](/filings/0001558370-25-006308.md) | [0.38](/filings/0001558370-25-009987.md) | [0.40](/filings/0001104659-25-105538.md) | not reported | [0.37](/filings/0001628280-26-029325.md) | [0.45](/filings/0001628280-26-051402.md) | [0.43](/filings/0001104659-25-105538.md) | not reported | [0.45](/filings/0001628280-26-029325.md) | [0.41](/filings/0001628280-26-051402.md) |
| Basic EPS | $ per share | [0.40](/filings/0001558370-24-014056.md) | not reported | [0.33](/filings/0001558370-25-006308.md) | [0.39](/filings/0001558370-25-009987.md) | [0.40](/filings/0001104659-25-105538.md) | not reported | [0.37](/filings/0001628280-26-029325.md) | [0.45](/filings/0001628280-26-051402.md) | [0.44](/filings/0001104659-25-105538.md) | not reported | [0.46](/filings/0001628280-26-029325.md) | [0.41](/filings/0001628280-26-051402.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [46.7](/filings/0001558370-23-017594.md) | [49.8](/filings/0001558370-25-011853.md) | [45.1](/filings/0001558370-24-006537.md) | [48.5](/filings/0001558370-24-010609.md) | [51.7](/filings/0001558370-24-014056.md) | [52.2](/filings/0001104659-26-024691.md) | [50.3](/filings/0001558370-25-006308.md) | [53.0](/filings/0001558370-25-009987.md) | [56.5](/filings/0001104659-25-105538.md) | [51.2](/filings/0001628280-26-051402.md) | [56.4](/filings/0001628280-26-029325.md) | [59.1](/filings/0001628280-26-051402.md) |
| Current assets | $m | [71.9](/filings/0001558370-23-017594.md) | [76.0](/filings/0001558370-25-011853.md) | [71.9](/filings/0001558370-24-006537.md) | [73.6](/filings/0001558370-24-010609.md) | [74.3](/filings/0001558370-24-014056.md) | [75.2](/filings/0001104659-26-024691.md) | [75.1](/filings/0001558370-25-006308.md) | [77.4](/filings/0001558370-25-009987.md) | [84.9](/filings/0001104659-25-105538.md) | [81.2](/filings/0001628280-26-051402.md) | [86.4](/filings/0001628280-26-029325.md) | [86.7](/filings/0001628280-26-051402.md) |
| Total assets | $m | [87.4](/filings/0001558370-23-017594.md) | [92.2](/filings/0001558370-25-011853.md) | [88.0](/filings/0001558370-24-006537.md) | [89.9](/filings/0001558370-24-010609.md) | [94.2](/filings/0001558370-24-014056.md) | [98.3](/filings/0001104659-26-024691.md) | [102](/filings/0001558370-25-006308.md) | [106](/filings/0001558370-25-009987.md) | [115](/filings/0001104659-25-105538.md) | [109](/filings/0001628280-26-051402.md) | [114](/filings/0001628280-26-029325.md) | [115](/filings/0001628280-26-051402.md) |
| Current liabilities | $m | [7.9](/filings/0001558370-23-017594.md) | [16.3](/filings/0001558370-25-011853.md) | [7.6](/filings/0001558370-24-006537.md) | [7.5](/filings/0001558370-24-010609.md) | [8.1](/filings/0001558370-24-014056.md) | [8.5](/filings/0001104659-26-024691.md) | [8.5](/filings/0001558370-25-006308.md) | [8.8](/filings/0001558370-25-009987.md) | [12.8](/filings/0001104659-25-105538.md) | [10.2](/filings/0001628280-26-051402.md) | [12.1](/filings/0001628280-26-029325.md) | [9.2](/filings/0001628280-26-051402.md) |
| Total liabilities | $m | [12.8](/filings/0001558370-23-017594.md) | [20.7](/filings/0001558370-25-011853.md) | [11.9](/filings/0001558370-24-006537.md) | [10.3](/filings/0001558370-24-010609.md) | [10.8](/filings/0001558370-24-014056.md) | [11.5](/filings/0001104659-26-024691.md) | [11.7](/filings/0001558370-25-006308.md) | [12.1](/filings/0001558370-25-009987.md) | [16.4](/filings/0001104659-25-105538.md) | [14.2](/filings/0001628280-26-051402.md) | [15.9](/filings/0001628280-26-029325.md) | [13.2](/filings/0001628280-26-051402.md) |
| Shareholders' equity | $m | [74.6](/filings/0001558370-24-014056.md) | [71.4](/filings/0001104659-26-024691.md) | [76.1](/filings/0001104659-25-105538.md) | [79.7](/filings/0001104659-25-105538.md) | [83.4](/filings/0001104659-25-105538.md) | [86.8](/filings/0001628280-26-051402.md) | [90.1](/filings/0001628280-26-051402.md) | [94.3](/filings/0001628280-26-051402.md) | [98.4](/filings/0001104659-25-105538.md) | [94.6](/filings/0001628280-26-051402.md) | [98.5](/filings/0001628280-26-051402.md) | [102](/filings/0001628280-26-051402.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [1,393 d](/filings/0001558370-24-014056.md) | [3,912 d](/filings/0001558370-25-011853.md) | [3,883](/filings/0001558370-25-006308.md) | [6,639 d](/filings/0001558370-25-009987.md) | [9,116 d](/filings/0001104659-25-105538.md) | [5,987 d](/filings/0001104659-26-024691.md) | [4,292](/filings/0001628280-26-029325.md) | [7,747 d](/filings/0001628280-26-051402.md) | [6,985 d](/filings/0001104659-25-105538.md) | [5,923 d](/filings/0001104659-26-024691.md) | [8,290](/filings/0001628280-26-029325.md) | [5,940 d](/filings/0001628280-26-051402.md) |
| Capital expenditure | $k | [308 d](/filings/0001558370-24-014056.md) | [532 d](/filings/0001558370-25-011853.md) | [271](/filings/0001558370-25-006308.md) | [1,134 d](/filings/0001558370-25-009987.md) | [3,810 d](/filings/0001104659-25-105538.md) | [2,790 d](/filings/0001104659-26-024691.md) | [3,697](/filings/0001628280-26-029325.md) | [2,636 d](/filings/0001628280-26-051402.md) | [1,138 d](/filings/0001104659-25-105538.md) | [294 d](/filings/0001104659-26-024691.md) | [403](/filings/0001628280-26-029325.md) | [185 d](/filings/0001628280-26-051402.md) |
| Dividends paid | $k | [0.0 d](/filings/0001558370-24-014056.md) | [0.0 d](/filings/0001558370-25-011853.md) | [7,976](/filings/0001558370-25-006308.md) | [1,900 d](/filings/0001558370-25-009987.md) | [1,900 d](/filings/0001104659-25-105538.md) | [1,901 d](/filings/0001104659-26-024691.md) | [2,162](/filings/0001628280-26-029325.md) | [2,161 d](/filings/0001628280-26-051402.md) | [2,163 d](/filings/0001104659-25-105538.md) | [8,554 d](/filings/0001104659-26-024691.md) | [2,556](/filings/0001628280-26-029325.md) | [2,557 d](/filings/0001628280-26-051402.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [12.6](/filings/0001558370-23-017594.md) | [12.7](/filings/0001558370-24-006537.md) | [12.7](/filings/0001558370-24-010609.md) | [12.7](/filings/0001558370-24-014056.md) | [12.7](/filings/0001558370-25-006308.md) | [12.8](/filings/0001558370-25-009987.md) | [12.8](/filings/0001104659-25-105538.md) | [12.8](/filings/0001628280-26-029325.md) | [12.8](/filings/0001628280-26-051402.md) | [12.9](/filings/0001104659-25-105538.md) | [12.9](/filings/0001628280-26-029325.md) | [12.9](/filings/0001628280-26-051402.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,786,991 at 2026-07-31, from the cover of the [10-Q filed 2026-07-31](/filings/0001628280-26-051402.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.